



Partnering Development milestone Digital health

4D Lifetec AG with first customers and R&D partner

05.03.2021 15:47



Based in Zug, 4D Lifetest aims to enable the early detection of cancers based on its proprietary CE-certified liquid biopsy model. With the first clients using the platform for lung cancer detection, the startup has entered a research and development collaboration with Volition, a US-based company, to inter alia speed up market penetration.

Founded in 2014 by an experienced team, 4D Lifetec AG developed its proprietary and fully patented 4D Lifetest for the early detection of cancer based on a new innovative biomarker and liquid biopsy. The test, which requires few millilitres of blood, consists of an algorithm-based instrument that combines a high sensitivity biomarker assay with a standardized workflow. This fast, cost-effective, and more precise assay holds a promise for oncology. It will also enable the earlier detection of multiple cancers, including lung, prostate, breast and colon cancer, thus significantly increasing patients' survival rate. The method is clinically validated and shows higher performance on early detection than current diagnostic methods, including conventional genomic liquid biopsy assays.

4D Lifetec's platform has the long term goal to be used as a stand-alone solution for preventive screening of non-symptomatic populations for personalised diagnostics. The first application based on this approach is 4D Lifetest Lung DX for personalised lung cancer diagnostics. With the CE certification obtained in February this year, 4D Lifetest LungDX has been launched in the Swiss market with a selected number of clients. In the current set up, the assay will be performed in certified labs run by hospitals. Further applications are under development.

Besides, the 4D Lifetest allows for patient inclusion, acting as a pre-selection test to detect early cancer. In combination with complementary assays, specific cancer typing is added for disease profiling, making it easy to deliver on a key promise of liquid biopsy by combining it with high specificity tests. To accelerate development in this field, the startup collaborates with various companies to accelerate new products for various applications.

R&D partnership with Volition

The company has recently entered a research and development partnership with VolitionRX, a US-based multinational epigenetics company developing simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases. The two will validate the complementarity of 4D Lifetec's 4D Lifetest and the Nu.Q tests developed by Volition in a combined clinical trial.

According to Arne Faisst, co-Founder and Chairman at 4D Lifetest, the partnership with Volition will speed up the development process and provide a gateway into new markets. With headquarters in the US and additional offices in Texas, London and Singapore,

Volition is also present in Belgium, California, with an R&D centre and a laboratory. Within the scope of their partnership, the two companies have initiated US commercialisation.

In the next stages, 4D Lifetec is working towards obtaining further CE certifications for further applications and establishing new strategic partnerships. The startup has already built a track record by winning investment from private investors and family offices from Switzerland and worldwide, and the Innosuisse grant (former CTI grant) in 2016. In 2019, the startup was among the ten winners of the Venture Leaders Life Sciences.

(RAN)

Photo: Oliver Schicht, Jacqueline Felber, Giancarlo Rizzoli

—

Comments

Please [login](#) or [sign up](#) to comment.

[Commenting guidelines](#)

Enter your comment.

send